AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02566915 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPET submaximal with EPAP
Description: The expiratory positive pressure is applied through silicone mask (RHDSON Vital Signs®, New Jersey, USA) containing one-way valve and a resistance mechanism expiratory positive expiratory pressure generator adjustable 5-20 cm H2O (Spring Loaded) (Vital Signs® , New Jersey, USA). The mask one headgear will be comfortably adjusted to face being used to prevent air leakage, and the pressure level gradually adjusted to the level of 10 cm H2O.
Study NCT03632798 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ChemoID assay
Description: The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill not only bulk of tumor cells, but importantly the cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse.
Study NCT01404468 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed ultrasound device with lidocaine
Description: Lidocaine (approximately 2 cc) was administered transdermally using a transducer (pulsed ultrasound)
Study NCT03632798 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ChemoID assay
Description: The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill not only bulk of tumor cells, but importantly the cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse.
Study NCT03632798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapies chosen by Physician or ChemoID assay are in the same list of FDA approved drugs to treat recurrent ovarian cancer.~Chemotherapy list:~* Liposomal Doxorubicin;~* Docetaxel;~* Paclitaxel;~* Carboplatin;~* Cisplatin;~* Gemcitabine;~* Topotecan;~* Carboplatin, Gemcitabine;~* Cisplatin, Gemcitabine;~* Carboplatin, Liposomal Doxorubicin;~* Carboplatin, Paclitaxel;~* Carboplatin, Docetaxel.
Study NCT03632798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapies chosen by Physician or ChemoID assay are in the same list of FDA approved drugs to treat recurrent ovarian cancer.~Chemotherapy list:~* Liposomal Doxorubicin;~* Docetaxel;~* Paclitaxel;~* Carboplatin;~* Cisplatin;~* Gemcitabine;~* Topotecan;~* Carboplatin, Gemcitabine;~* Cisplatin, Gemcitabine;~* Carboplatin, Liposomal Doxorubicin;~* Carboplatin, Paclitaxel;~* Carboplatin, Docetaxel.
Study NCT02341872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinpro White Varnish (fluoride + calcium varnish)
Description: Clinpro White Varnish will be applied to the teeth with brush.
Study NCT02341872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinpro White Varnish (fluoride + calcium varnish)
Description: Clinpro White Varnish will be applied to the teeth with brush.
Study NCT02341872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Curodont Repair
Description: Curodont Repair solution be applied to the teeth in the form of drops
Study NCT01404468 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: off device
Description: off device with Lidocaine (approximately 2 cc) was administered transdermally
Study NCT04369885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Go Home tablet with linked GoSpiro and 3230 Pulse Oximeter
Description: All participants will receive the intervention consisting of a home telemedicine tablet platform (GoHome) that will collect multiple spirometry tests each week (including both forced and slow spirometry measurements), pulse oximetry, and QoL Questionnaire responses. The platform will remind patients to take their medications remind patients to perform measurements, send patients helpful information, and execute a UNC clinic established COPD Action Plan.The backend of the platform is a remote server (Monitored Therapeutics CarePortal) that collects the data, send out alerts to the Principal Investigator and can track and trend the data for them.
Study NCT00685711 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Cat-PAD
Description: single, escalating dose intradermal and subcutaneous injections of Cat-PAD
Study NCT01404468 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous ultrasound device with lidocaine
Description: Lidocaine (approximately 2 cc) was administered transdermally using a transducer (continuous ultrasound )
Study NCT02562313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone insulin lispro
Description: BioChaperone insulin lispro bolus infusion followed by test meal intake
Study NCT02562313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog®
Description: Humalog® bolus infusion followed by test meal intake
Study NCT00685711 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cat-PAD
Description: single, escalating dose intradermal and subcutaneous injections of Cat-PAD
Study NCT02020421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Low frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) over the center of the right Pars Triangularis for 15 minutes (900 pulses) prior to each Speech-Language therapy session. Stimulation intensity will be set at 90% of the resting motor threshold (RMT) of the left first dorsal interosseous (FDI) muscle.
Study NCT02020421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: 2mA cathodal transcranial direct current stimulation (tDCS) over the right Pars Triangularis. The anode will be placed on the forehead over the contralateral eye. tDCS will start immediately before the speech-language therapy session and last throughout the session.
Study NCT02020421 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Low frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) over the Vertex for 15 minutes (900 pulses) prior to each Speech-Language therapy session. Stimulation intensity will be set at 10% of the resting motor threshold (RMT) of the left first dorsal interosseous (FDI) muscle.
Study NCT02020421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS
Description: Low frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) over the Vertex for 15 minutes (900 pulses) prior to each Speech-Language therapy session. Stimulation intensity will be set at 10% of the resting motor threshold (RMT) of the left first dorsal interosseous (FDI) muscle.
Study NCT02020421 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham cathodal transcranial direct current stimulation (tDCS) over the right Pars Triangularis. The anode will be placed on the forehead over the contralateral eye. To elicit the typical skin sensation of real tDCS (tingling sensation on the skin when tDCS is turned on and off), the current will be turned on for 30 seconds and then turned off for the duration of the speech-language therapy session. The same procedure will be done at the end of the session.
Study NCT02020421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: Sham cathodal transcranial direct current stimulation (tDCS) over the right Pars Triangularis. The anode will be placed on the forehead over the contralateral eye. To elicit the typical skin sensation of real tDCS (tingling sensation on the skin when tDCS is turned on and off), the current will be turned on for 30 seconds and then turned off for the duration of the speech-language therapy session. The same procedure will be done at the end of the session.
Study NCT02896621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone plus amiloride
Description: A capsule with chlorthalidone plus amiloride was taken once daily in the morning for eight weeks.
Study NCT02896621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: A capsule of amlodipine was taken once daily in the morning for eight weeks.
Study NCT05297149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Description: The hippotherapy program consisted of 6 weekly sessions that varied in duration between 20 and 30 minutes depending on the weekly program and the participant's condition. Each session started with brief greetings and contact with the horse.
Study NCT05297149 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home exrecises
Description: The home exercise program consisted of the following balance training exercises: one leg standing on foam with eyes open and closed, double leg standing on foam with eyes open and closed, walking in tandem with eyes open and closed, balance exercises on an inclined surface, balance exercises in squat, and jumping over an obstacle on the ground. All participants performed the exercises under parental supervision, 3 times per week for 6 weeks. The physiotherapist made video calls to the children and parents to ensure their adherence to the home exercise program.
Study NCT04292756 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subtenon injection of 40 mg triamcinolone acetonide
Description: Subtenon injection of 40 mg triamcinolone acetonide: 1 initial injection of 40 mg triamcinolone acetonide, further injections will be base at month 3 examination.
Study NCT00554385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: Up to 4 capsules will be taken once daily for 12 months. Dosage forms include 1 mg, 5 mg, 10 mg capsules and 40 mg tablets. Highest dose allowed is 80 mg per day.
Study NCT03632369 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperpolarized xenon-129 MRI
Description: Participants will be asked to inhale the xenon-129 contrast agent according to procedure for gas administration. The success criterion of the drug is a obtained Xe MRI lung image with reasonable signal level. The clinical MRI scanner Philips Achieva 3.0T will be equipped with 129Xe Quadrature Transreceive Lung Coil (Large and Small) to acquire 129Xe lung images. The resonator length of the large coils is equal to 122 cm, whereas the same size of the small coil is equal to 106 cm. The success criterion of the device performance is the obtained reasonable Xe MRI lung image.
Study NCT01298804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Education and Activated Referral to Care
Description: The intervention represents an integrated identification and intervention system based on the evidence-based construct of screening, brief intervention, and referral to treatment (SBIRT). Within the comprehensive case management services of Head Start, eligible women will be randomized to receive either usual care or the Head Start-based intervention. In our intervention, mothers at risk for depression will receive a problem-solving intervention; depression symptom monitoring; and an Activated referral to more definitive services for those who have worsening symptoms over time.
Study NCT01341275 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B vaccine
Description: 10 ug dose, one-time administration
Study NCT01341275 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B vaccine
Description: 20 ug dose, one-time administration
Study NCT03303235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylergonovine
Description: IV vs IM
Study NCT03303235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylergonovine
Description: IV vs IM
Study NCT03411161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy (S81694 + paclitaxel) phase I
Description: Dose escalation S 81694 (IV); paclitaxel started at 80 mg/m²,(IV)
Study NCT03411161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (IV) at 80 mg/m²/week
Study NCT03411161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy (S81694 + paclitaxel) phase II
Description: S 81694 (IV) at RP2D; paclitaxel (IV) at 80 mg/m²/week
Study NCT03875508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Risankizumab to be injected subcutaneously (SC)
Study NCT03875508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autoinjector
Description: Single dose pre-filled autoinjector containing risankizumab for SC injection
Study NCT02643524 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition and Exercise Counseling
Description: Patients are prescribed CAM boot and provided nutritional and upper body exercise counseling at the time the CAM boot is dispensed. Patients will be given a diary to complete their daily meal intake (optional), seated upper body physical exercise guidelines and asked to perform them three days per week and each exercise three times per session if able. They will be asked to record number of hours CAM boot is worn daily in the Patient Diary, if one is utilized. Albumin lab test will be drawn and their height and weight measured.
Study NCT02643524 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients are prescribed CAM boot. No nutritional or exercise guidelines will be provided. Patients will be given a diary to complete their daily meal intake and physician exercise (if any) and number of hours CAM boot is worn daily. Albumin lab test will be drawn and their height and weight measured.
Study NCT01093404 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thrombus aspiration
Description: Aspiration of thrombus material before angioplasty
Study NCT04292756 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection of 4 mg triamcinolone acetonide
Description: Intravitreal injection of 4 mg triamcinolone acetonide: 1 initial injection of 4 mg triamcinolone acetonide, further injections will be base at month 3 examination.
Study NCT04292756 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visometry
Description: Ophthalmic examination
Study NCT04292756 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fluorescent angiography
Description: Ophthalmic examination
Study NCT04292756 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Refractometry
Description: Ophthalmic examination
Study NCT04292756 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Slit lamp examination
Description: Ophthalmic examination
Study NCT04292756 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ophthalmoscopy
Description: Ophthalmic examination
Study NCT04292756 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: OKT
Description: Ophthalmic examination
Study NCT01727193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 1 glucocorticoid + Azathioprine: Glucocorticoid (0.25mg/kg/d )plus Azathioprine at a starting dose of 50mg/d for 14 days, then increase up to 2mg/kg in 2 weeks.If no adverse events occurred , maintain the dose until 48 weeks.
Study NCT01727193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide
Description: The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 2 glucocorticoid + Leflunomide: Glucocorticoid (0.25mg/kg/d )plus Leflunomide 20mg/d for adult, 10mg/d for child. if no adverse events occurred , maintain the dose until 48 weeks.
Study NCT00763087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weightbearing exercise
Description: All subjects in the exercise group will participate, as able, in 3 supervised 1 hour exercise sessions per week for the first month and 2 supervised and 1 unsupervised exercise session per week for the remaining 2 months. Subjects in each exercise group will be seen on alternating times to avoid cross contamination of treatment intervention. Walking intensity for all subjects will be applied with the intent to exceed their routine physical stress level, and therefore incur positive adaptations to physical stress, but not exceed their threshold for injury.
Study NCT00763087 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nonweightbearing exercise
Description: All subjects in the 2 exercise groups will participate, as able, in 3 supervised 1 hour exercise sessions per week for the first month and 2 supervised and 1 unsupervised exercise session per week for the remaining 2 months. Subjects in each exercise group will be seen on alternating times to avoid cross contamination of treatment intervention. Biking intensity for all subjects will be applied with the intent to exceed their routine physical stress level, and therefore incur positive adaptations to physical stress, but not exceed their threshold for injury.
Study NCT00763087 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: nonexercising control
Description: All subjects will be instructed, verbally and with written documents, regarding appropriate foot and skin care twice per month.
Study NCT01037699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFSH: Follicle Stimulating Hormone
Study NCT01037699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)
Study NCT01276860 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Psychomotor Vigilance Testing
Description: The purpose of this study is to examine the use of psychomotor vigilance testing (PVT) as a tool in the diagnosis and prediction of pediatric obstructive sleep apnea. PVT simply involves responding to a light by pressing a button on a small handheld device. It is a simple measure of reaction time.
Study NCT01093404 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration
Description: Aspiration of thrombus material before angioplasty
Study NCT02092090 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary sodium reduction
Description: Ongoing dietary advice and a supply of a reduced-sodium added-potassium salt substitute
Study NCT03178058 — intervention group
Intervention type: OTHER
Intervention: Questionaire
Description: Prior to surgery women will be given a questionnaire detailing previous motion sickness, previous history of PONV, emesis during pregnancy, smoking history , itching history, skin atopy and allergies. After surgery details about surgery will be added: intraoperative hypotension, use of phenylepherine, intraoperative nausea and vomiting, exteriorization of uterus, extent of adhesions, need for uterotonic medications, and estimated bleeding.~Parturients will be assessed 1 hour and 24 postoperatively by attending anesthesiologist, PONV incidence will be reported using a three point ordinal scale (0 = none, 1 = nausea, 2 = retching, 3 =vomiting).
Study NCT04458714 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aortoiliac angioplasty
Description: In the CO2 arm we used manual injection of CO2 from a medicinal CO2 cylinder connected to a particle filter. Under water aspiration was used to prevent air contamination. Using a twenty mls syringe the required amount of CO2was aspirated using a three way tap and was followed my aspirating 3mls of saline to provide a fluid barrier. In the ICM arm the injection of contrast was done using 10-ml syringes with 5 mls of iodinated contrast media and 5 mls of saline solution per injection. The ICM used in all cases was Omnipaque 300 (Iohexol), a nonionic low osmolar contrast commonly in use in both hospitals.
Study NCT02561130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Dose is titrated to achieve fasting normoglycemia
Study NCT00657709 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)
Description: One dose of rMenB Lot concomitantly with the routinely administered infant vaccines
Study NCT02561130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Dose is titrated to 1 g bid or maximal tolerated dose
Study NCT02561130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forxiga
Description: Dose is titrated to 10 mg po daily or maximal tolerated dose
Study NCT02561130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle therapy
Description: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
Study NCT02405416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infrahepatic inferior vena cava clamping
Description: Infrahepatic inferior vena cava is clamped in hepatectomy.
Study NCT02405416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective hepatic vascular exclusion
Description: Selected major hepatic vein is clamped in hepatectomy.
Study NCT02405416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Portal triad clamping
Description: Portal triad are clamped in hepatectomy.